235 related articles for article (PubMed ID: 35562666)
21. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).
Woldemeskel BA; Karaba AH; Garliss CC; Beck EJ; Wang KH; Laeyendecker O; Cox AL; Blankson JN
Clin Infect Dis; 2022 Apr; 74(7):1268-1270. PubMed ID: 34293114
[TBL] [Abstract][Full Text] [Related]
22. Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals.
Samanovic MI; Cornelius AR; Gray-Gaillard SL; Allen JR; Karmacharya T; Wilson JP; Hyman SW; Tuen M; Koralov SB; Mulligan MJ; Herati RS
Sci Transl Med; 2022 Feb; 14(631):eabi8961. PubMed ID: 34874183
[TBL] [Abstract][Full Text] [Related]
23. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
24. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
25. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
[TBL] [Abstract][Full Text] [Related]
26. Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people.
Vitallé J; Pérez-Gómez A; Ostos FJ; Gasca-Capote C; Jiménez-León MR; Bachiller S; Rivas-Jeremías I; Silva-Sánchez MDM; Ruiz-Mateos AM; Martín-Sánchez MÁ; López-Cortes LF; Rafii-El-Idrissi Benhnia M; Ruiz-Mateos E
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35943812
[TBL] [Abstract][Full Text] [Related]
27. Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients.
Hurme A; Jalkanen P; Heroum J; Liedes O; Vara S; Melin M; Teräsjärvi J; He Q; Pöysti S; Hänninen A; Oksi J; Vuorinen T; Kantele A; Tähtinen PA; Ivaska L; Kakkola L; Lempainen J; Julkunen I
Front Immunol; 2022; 13():869990. PubMed ID: 35529867
[TBL] [Abstract][Full Text] [Related]
28. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
[TBL] [Abstract][Full Text] [Related]
29. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
[TBL] [Abstract][Full Text] [Related]
31. Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.
Saresella M; Piancone F; Marventano I; Hernis A; Trabattoni D; Invernizzi M; La Rosa F; Clerici M
Front Immunol; 2022; 13():947320. PubMed ID: 36072604
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
Podrazil M; Taborska P; Stakheev D; Rataj M; Lastovicka J; Vlachova A; Pohunek P; Bartunkova J; Smrz D
Front Immunol; 2022; 13():892277. PubMed ID: 35669765
[TBL] [Abstract][Full Text] [Related]
33. BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality.
Jung MK; Jeong SD; Noh JY; Kim DU; Jung S; Song JY; Jeong HW; Park SH; Shin EC
Nat Microbiol; 2022 Jun; 7(6):909-917. PubMed ID: 35577972
[TBL] [Abstract][Full Text] [Related]
34. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
36. Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273.
Grunau B; Golding L; Prusinkiewicz MA; Asamoah-Boaheng M; Armour R; Marquez AC; Jassem AN; Barakauskas V; O'Brien SF; Drews SJ; Haig S; Lavoie PM; Goldfarb DM
Microbiol Spectr; 2022 Apr; 10(2):e0270221. PubMed ID: 35254166
[TBL] [Abstract][Full Text] [Related]
37. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
38. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
Viruses; 2022 May; 14(5):. PubMed ID: 35632698
[TBL] [Abstract][Full Text] [Related]
39. Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.
Baron F; Canti L; Ariën KK; Kemlin D; Desombere I; Gerbaux M; Pannus P; Beguin Y; Marchant A; Humblet-Baron S
Front Immunol; 2022; 13():827242. PubMed ID: 35309332
[TBL] [Abstract][Full Text] [Related]
40. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose.
Renia L; Goh YS; Rouers A; Le Bert N; Chia WN; Chavatte JM; Fong SW; Chang ZW; Zhuo NZ; Tay MZ; Chan YH; Tan CW; Yeo NK; Amrun SN; Huang Y; Wong JXE; Hor PX; Loh CY; Wang B; Ngoh EZX; Salleh SNM; Carissimo G; Dowla S; Lim AJ; Zhang J; Lim JME; Wang CI; Ding Y; Pada S; Sun LJ; Somani J; Lee ES; Ong DLS; ; Leo YS; MacAry PA; Lin RTP; Wang LF; Ren EC; Lye DC; Bertoletti A; Young BE; Ng LFP
Nat Commun; 2022 Aug; 13(1):4615. PubMed ID: 35941158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
